利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.033 秒)

    Sustained release pharmaceutical composition
    3.
    发明申请
    Sustained release pharmaceutical composition 失效
    持续释放药物组合物

    公开(公告)号：US20050100603A1

    公开(公告)日：2005-05-12

    申请号：US10843005

    申请日：2004-05-10

    申请人： Kazuhiro Sako ,  Toyohiro Sawada ,  Hiromu Kondo ,  Keiichi Yoshihara ,  Hiroyuki Kojima

    发明人： Kazuhiro Sako ,  Toyohiro Sawada ,  Hiromu Kondo ,  Keiichi Yoshihara ,  Hiroyuki Kojima

    IPC分类号： A61K9/00 ,  A61K9/06 ,  A61K9/16 ,  A61K9/22 ,  A61K9/26 ,  A61K9/34 ,  A61K31/18

    CPC分类号： A61K31/18

    摘要： [Problem] As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting at present, it is needed to provide a sustained-release pharmaceutical composition in which the efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited in the dosage and it is also needed to provide a method for administration of tamsulosin hydrochloride in which the adverse reactions accompanied by therapy or prevention on the basis of an α1 receptor blocking action are reduced. [Means for Resolution] A sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin/Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (Cmin) to the maximum plasma tamsulosin concentration after the administration (Cmax) is about 0.4 or more.

    摘要翻译： [问题]与目前已经提供给医疗环境的目前含有盐酸坦索罗辛的口服缓释制剂相比，需要提供一种缓释药物组合物，其功效相当于甚至更好，不良事件 如不良反应（例如，姿势低血压）降低，可以增加剂量，并且如果需要，食物的摄入不限于剂量，并且还需要提供一种施用盐酸坦洛新的方法，其中不良反应 伴随着基于α1受体阻断作用的治疗或预防。 [解决方法]一种持续释放药物组合物，其特征在于，含有坦索罗辛或其药学上可接受的盐和缓释药物组合物的载体，其比例（C min / 给药后24小时血浆坦索罗辛浓度与给药后的最大血浆坦索罗辛浓度（C ）相比较，差异有统计学意义（C < SUB> max ）为约0.4以上。

    Sustained release pharmaceutical composition
    10.
    发明申请
    Sustained release pharmaceutical composition 失效
    持续释放药物组合物

    公开(公告)号：US20050100602A1

    公开(公告)日：2005-05-12

    申请号：US10842809

    申请日：2004-05-10

    申请人： Kazuhiro Sako ,  Toyohiro Sawada ,  Keiichi Yoshihara ,  Hiroyuki Kojima

    发明人： Kazuhiro Sako ,  Toyohiro Sawada ,  Keiichi Yoshihara ,  Hiroyuki Kojima

    IPC分类号： A61K9/00 ,  A61K9/20 ,  A61K31/18 ,  A61K9/22

    CPC分类号： A61K9/0065 ,  A61K9/0004 ,  A61K9/2013 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2086 ,  A61K31/18

    摘要： [Problem] As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting, there is a problem to provide a sustained-release pharmaceutical composition in which efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited. [Means for Resolution] A sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and, when dissolution test is carried out according to Japanese Pharmacopoeia Dissolution Test Method 2, the tamsulosin release after 7 hours from the start of the dissolution is about 20 to about 85%.

    摘要翻译： [问题]与目前已经提供给药物的盐酸坦洛新的口服缓释制剂相比，存在着提供功效等同或更好的缓释药物组合物的问题，不良反应如 不良反应（例如，姿势性低血压）降低，可以增加剂量，如果需要，摄取食物不受限制。 [解决方法]一种持续释放药物组合物，其特征在于，含有坦索罗辛或其药学上可接受的盐和缓释药物组合物的载体，当根据日本药典溶出度试验进行溶出试验时 方法2，溶出开始7小时后的坦索罗辛释放量为约20％至约85％。